The Team Behind BioMedAI

Jenny Feng

Before joining the faculty at BU Law, Jenny Feng was a senior counsel in the financial service and banking industry, providing legal advice on asset management operations, funds formation, structuring and strategies, as well as a variety of regulatory and governance matters. Jenny negotiated complex financial and commercial contracts with multi-jurisdictional asset and wealth managers, insurers, banks and private equity funds. Prior to that, she oversaw all aspects of legal affairs for startups and small businesses in the biotech industry. She worked with large law firms in various regions, including New York, Hong Kong and Shanghai. In her earlier career, Jenny served as a public service fellow for the Honorable Elizabeth Stong in the U.S. Bankruptcy Court for the Eastern District of New York and interned at the U.S. Securities and Exchange Commission (SEC) and Financial Industry Regulatory Authority (FINRA).

Rui (Rio) Cao

Started in cell culture, ended up in national sales—but the common thread is simple: I build things that grow. Now I’m culturing accounts, teams, and projects with slightly fewer contamination events haha! Biopharma is my industry. People are my specialty. And my coffees-per-day curve shows no signs of plateauing.

Elena Chernokalskaya

Zack Li

Chao Yang

I have strong experiences on the development of computational protocols for structure-based inhibitor design, such as protein-ligand scoring function development (both classical and machine-learning methods). Prospective virtual screening of compound library in early-stage drug discovery.

Wenliang Zhang

I am an AI scientist and entrepreneur with over a decade of experience in immuno-oncology, infectious diseases, and computational biology. With a Master’s degree in Computer Science and a PhD in Infectious Diseases, my work sits at the intersection of machine learning, software engineering, and drug discovery. I am the founder of Wedaita, where I am building BioMedAI, an AI-driven platform designed to accelerate drug discovery and shorten the time required to bring life-saving therapies to patients using generative AI and autonomous multi-agent workflows. My focus is on developing end-to-end AI systems that integrate biological data, predictive modeling, and scalable software infrastructure to enable faster and more efficient therapeutic development. My goal is to leverage AI to fundamentally transform how drugs are discovered, designed, and optimized.